Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes
- 1 January 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 182 (1) , 416-423
Abstract
Peptide mimotopes of the CD20 epitope recognized by rituximab are useful tools for studying this therapeutic mAb’s functional properties. We previously identified two structurally different peptides that are both effective mimotopes: a 7-mer cyclic peptide (Rp15-C) bearing the antigenic motif a/sNPS that matches 170 ANPS 173 of the extracellular loop of CD20, and a 12-mer linear peptide (Rp5-L) containing the antigenic motif WPxWLE lacking sequence homology to CD20. In this study, we investigated whether the different structures of Rp15-C and Rp5-L reflect the mimicry of the same or different CD20 epitopes recognized by rituximab. Using immunochemical methods, we found that, like Rp15-C, Rp5-L mimics the raft-associated form of CD20 (by inhibiting rituximab binding to CD20 in vitro). Rp5-L and Rp15-C elicit, in immunized mice, anti-CD20 Abs that stain CD20+ cells with a punctate pattern similar to that of rituximab. However, only anti-Rp5-L Abs recognize denatured CD20. When phage-display peptide libraries were panned with anti-Rp5-L, phage clones were enriched that expressed the consensus qWPxwL, similar to the antigenic motif WPxWLE , but not matching a/sNPS . Finally, WPxWLE and ANPS share some, but not all, contact sites within the rituximab Ag-combining site, indicating that WPxWLE is not an exact replica of Rp15-C (or CD20) ANPS . Altogether, these results indicate that the two structurally different peptides are also conformationally different, and suggest that rituximab recognizes two different CD20-associated epitopes.Keywords
This publication has 39 references indexed in Scilit:
- Mechanisms of killing by anti-CD20 monoclonal antibodiesMolecular Immunology, 2007
- Hot-spot mimicry of a cytokine receptor by a small moleculeProceedings of the National Academy of Sciences, 2006
- The epitope recognized by rituximabBlood, 2006
- Rituximab but not Other anti-CD20 Antibodies Reverses Multidrug Resistance in 2 B lymphoma Cell Lines, Blocks the Activity of P-glycoprotein (P-gp), and Induces P-gp to Translocate out of Lipid RaftsJournal of Immunotherapy, 2006
- Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursorBlood, 2006
- Probing Fragment Complementation by Rigid-Body Docking: in Silico Reconstitution of Calbindin D9kJournal of Chemical Information and Modeling, 2005
- CD20 Mimicry by a mAb Rituximab-Specific Linear Peptide: A Potential Tool for Active Immunotherapy of Autoimmune DiseasesAnnals of the New York Academy of Sciences, 2005
- Mouse opens door for study of autoimmune diseases2004
- A cholesterol-dependent CD20 epitope detected by the FMC7 antibodyLeukemia, 2003
- Murine antiidiotypic monoclonal antibodies that bear the internal image of HLA-DR allospecificities.Journal of Clinical Investigation, 1989